|
[1]BARGE S, GRANDO V, NAULT JC, et al.Prevalence and clinical significance of nodular regenerative hyperplasia in liver biopsies[J].Liver Int, 2016, 36 (7) :1059-1066.
|
|
[2]HARTLEB M, GUTKOWSKI K, MILKIEWICZ P.Nodular regenerative hyperplasia:Evolving concepts on underdiagnosed cause of portal hypertension[J].World J Gastroenterol, 2011, 17 (11) :1400-1409.
|
|
[3]BISSONNETTE J, GENEREUX A, COTE J, et al.Hepatic hemodynamics in 24 patients with nodular regenerative hyperplasia and symptomatic portal hypertension[J].J Gastroenterol Hepatol, 2012, 27 (8) :1336-1340.
|
|
[4]LAL BK, STANLEY A.Nodular regenerative hyperplasia related portal hypertension in a patient with hypogammaglobulinaemia[J].World J Gastroenterol, 2013, 19 (22) :3502-3504.
|
|
[5]TRIPATHI D, FERGUSON JW, THERAPONDOS G, et al.Review article:recent advances in the management of bleeding gastric varices[J].Aliment Pharmacol Ther, 2006, 24 (1) :1-17.
|
|
[6]MANZIA TM, GRAVANTE G, di PAOLO D, et al.Liver transplantation for the treatment of nodular regenerative hyperplasia[J].Dig Liver Dis, 2011, 43 (12) :929-934.
|
|
[7]ALVAREZ-LARRAN A, ABRALDES JG, CERVANTES F, et al.Portal hypertension secondary to myelofibrosis:A study of three cases[J].Am J Gastroenterol, 2005, 100 (10) :2355-2358.
|
|
[8]TAN HK, LEOW WQ, CHANG PE.Ruxolitinib for the Treatment of Portal Hypertension in a Patient With Primary Myelofibrosis[J].Gastroenterology, 2017.[Epub ahead of print]
|
|
[9]VERSTOVSEK S, MESA RA, GOTLIB J, et al.A doubleblind, placebo-controlled trial of ruxolitinib for myelofibrosis[J].N Engl J Med, 2012, 366 (9) :799-807.
|
|
[10]VERSTOVSEK S, MESA RA, GOTLIB J, et al.Long-term treatment with ruxolitinib for patients with myelofibrosis:5-year update from the randomized, double-blind, placebocontrolled, phase 3 COMFORT-I trial[J].J Hematol Oncol, 2017, 10 (1) :55.
|
|
[11]MARCHETTI M, BAROSI G, CERVANTES F, et al.Which patients with myelofibrosis should receive ruxolitinib therapy?ELN-SIE evidence-based recommendations[J].Leukemia, 2017, 31 (4) :882-888.
|
|
[12]YAN M, GEYER H, MESA R, et al.Clinical features of patients with philadelphia-negative myeloproliferative neoplasms complicated by portal hypertension[J].Clin Lymphoma Myeloma Leuk, 2015, 15 (1) :e1-e5.
|
|
[13]GENTILUCCI UV, GALLO P, PERRONE G, et al.Non-cirrhotic portal hypertension with large regenerative nodules:Adiagnostic challenge[J].World J Gastroenterol, 2011, 17 (20) :2580-2584.
|
|
[14]GRTZEN J, HUNKA LM, VONNAHME M, et al.γ-Glutamyl transferase is an independent biomarker of splanchnic thrombosis in patients with myeloproliferative neoplasm[J].Medicine (Baltimore) , 2016, 95 (20) :e3355.
|
|
[15]REILLY CR, BABUSHOK DV, MARTIN K, et al.Multicenter analysis of the use of transjugular intrahepatic portosystemic shunt (TIPS) for management of MPN-associated portal hypertension[J].Am J Hematol, 2017, 92 (9) :909-914.
|
|
[16]SAMUELSON BT, VESELY SK, CHAI-ADISAKSOPHA C, et al.The impact of ruxolitinib on thrombosis in patients with polycythemia vera and myelofibrosis:A meta-analysis[J].Blood Coagul Fibrinolysis, 2016, 27 (16) :648-652.
|
|
[17]PIERI L, PAOLI C, ARENA U, et al.Safety and efficacy of ruxolitinib in splanchnic vein thrombosis associaged with myeloproliferative neoplasms[J].Am J Hematol, 2017, 92 (9) :187-195.
|
|
[18]ZHAO G, WU ZY, ZHANG B, et al.Diagnosis and treatment of portal hypertension secondary to myeloproliferative disorders:A report of three cases[J].J Dig Dis, 2011, 12 (4) :312-316.
|
|
[19]GIANOTTI R, CHARLES H, HYMES K, et al.Treatment of gastric varices with partial splenic embolization in a patient with portal vein thrombosis and a myeloproliferative disorder[J].World J Gastroenterol, 2014, 20 (39) :14495-14499.
|
|
[20] WEHRMAN A, KRIEGERMEIER A, WEN J, et al.Diagnosis and management of hepatobiliary complications in autosomal recessive polycystic kidney disease[J].Front Pediatr, 2017, 5:124.
|
|
[21]UMAR J, JOHN S.Caroli Disease[M].SourceStatPearls[Internet].Treasure Island (FL) :Stat Pearls Publishing, 2018.
|
|
[22]MOSLIM MA, GUNASEKARAN G, VOGT D, et al.Surgical management of Caroli's disease:Single center experience and review of the literature[J].J Gastrointest Surg, 2015, 19 (11) :2019-2027.
|
|
[23]JANOWSKI K, GOLISZEK M, CIELECKA-KUSZYK J, et al.Congenital hepatic fibrosis in a 9-year-old female patienta case report[J].Clin Exp Hepatol, 2017, 3 (3) :176-179.
|
|
[24]MAZIGH MS, ALOUI N, FETNI I, et al.Congential hepatic fibrosis in children.Report of 9 cases and review of the literature[J].Tunis Med, 2006, 84 (3) :182-188.
|
|
[25]SRINATH A, SHNEIDER BL.Congenital hepatic fibrosis in a 9-year-old female patient-a case report[J].Clin Exp Hepatol, 2017, 3 (3) :176-179.
|
|
[26]MILLWALA F, SEGEV DL, THULUVATH PJ, et al.Caroli's disease and outcomes after liver transplantation[J].Liver Transpl, 2008, 14 (1) :11-17.
|
|
[27]CHANDOK N.Polycystic liver disease:A clinical review[J].Ann Hepatol, 2012, 11 (6) :819-826.
|
|
[28]QIAN Q.Isolated polycystic liver disease[J].Adv Chronic Kidney Dis, 2010, 17 (2) :181-189.
|
|
[29]GEVERS TJ, DRENTH JP.Somatostatin analogues for treatment of polycystic liver disease[J].Curr Opin Gastroenterol, 2011, 27 (3) :294-300.
|
|
[30]HOGAN MC, MASYUK TV, PAGE L, et al.Somatostatin analog therapy for severe polycystic liver disease:Results after 2years[J].Nephrol Dial Transplant, 2012, 27 (9) :3532-3539.
|
|
[31]QIAN Q, DU H, KING BF, et al.Sirolimus reduces polycystic liver volume in ADPKD patients[J].J Am Soc Nephrol, 2008, 19 (3) :631-638.
|
|
[32]KHAN MS, KHAN Z, JAVAID T, et al.Isolated polycystic liver disease:An unusual cause of recurrent variceal bleed[J].Case Rep Gastrointest Med, 2018, 2018:2902709.
|
|
[33]van KEIMPEMA L, NEVENS F, ADAM R, et al.Excellent survival after liver transplantation for isolated polycystic liver disease:An European liver transplant registry study[J].Transpl Int, 2011, 24 (12) :1239-1245.
|
|
[34]JAMES SP, STROMEYER FW, CHANG C, et al.Liver abnormalities in patients with Gaucher's disease[J].Gastroenterology, 1981, 80 (1) :126-133.
|
|
[35]CANO RUIZ A, MARTíN SCAPA A, MONESCILLO FRANCIA A, et al.Gaucher’s disease type 1:An infrequent cause of portal hypertension[J].Ann Med Interna, 1998, 15 (9) :483-484.
|
|
[36]BANDYOPADHYAY R, BANDYPADHYAY S, MAITY PK.Gauchers disease presenting with portal hypertension[J].Indian Pediatr, 2011, 48 (10) :801-802.
|
|
[37]REGENBOOG M, van DUSSEN L, VERHEIJ J, et al.Hepatocellular carcinoma in Gaucher disease:An international case series[J], J Inherit Metab Dis, 2018, 41 (5) :819-827.
|
|
[38]ADAR T, ILAN Y, ELSTEIN D, et al.Liver involvement in Gaucher disease-review and clinical approach[J].Blood Cells Mol Dis, 2018, 68:66-73.
|
|
[39]AYTO RM, HUGHES DA, JEEVARATNAM P, et al.Longterm outcomes of liver transplantation in type 1 Gaucher disease[J].Am J Transplant, 2010, 10 (8) :1934-1039.
|
DownLoad: